The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial.
 
Andrew James Weickhardt
Honoraria - Eisai; Ipsen
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen
 
Farshad Foroudi
No Relationships to Disclose
 
Shomik Sengupta
No Relationships to Disclose
 
Laura Galletta
No Relationships to Disclose
 
Alan Herschtal
No Relationships to Disclose
 
Peter S. Grimison
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Halozyme (Inst); MSD (Inst); Pfizer (Inst); Specialised Therapeutics (Inst); Tigermed (Inst); Tigermed (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - IPSEN
 
Nitya Patanjali
No Relationships to Disclose
 
Siobhan Ng
No Relationships to Disclose
 
Colin Tang
No Relationships to Disclose
 
Robert Goodwin
No Relationships to Disclose
 
Elizabeth J. Hovey
No Relationships to Disclose
 
Tom Jarvis
No Relationships to Disclose
 
Colin Chen
No Relationships to Disclose
 
Shahneen Kaur Sandhu
Honoraria - Amgen; Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck
 
Keen Hun Tai
No Relationships to Disclose
 
Nathan Lawrentschuk
No Relationships to Disclose
 
Ian D. Davis
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Exelixis (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.